Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Jul;7(4):241-7.
doi: 10.1007/s11912-005-0045-6.

Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer

Brian J Byrne  1 , Jennifer Garst
Affiliations
Review

Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer

Brian J Byrne et al. Curr Oncol Rep. 2005 Jul.

Abstract

The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration, whereas cetuximab is being studied for use in NSCLC. Erlotinib has shown a survival advantage in patients with advanced NSCLC. Further studies have identified female sex, nonsmokers, Asian race, good performance status, and adenocarcinoma histology as predictors of patient response to these agents. A genetic mutation in EGFR has also been correlated with an increase in response.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clin Cancer Res. 2000 Dec;6(12):4885-92 - PubMed
    1. J Clin Oncol. 2004 Mar 1;22(5):777-84 - PubMed
    1. J Clin Oncol. 2005 Sep 1;23(25):5892-9 - PubMed
    1. Exp Cell Res. 2003 Mar 10;284(1):122-30 - PubMed
    1. J Clin Oncol. 2003 Jun 1;21(11):2094-100 - PubMed

MeSH terms